Invesco’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-437,868
| Closed | -$17.6M | – | 3830 |
|
|
2026
Q1 | $17.6M | Buy |
437,868
+211,892
| +94% | +$4.57M | ﹤0.01% | 1517 |
|
|
2025
Q4 | $5.68M | Buy |
225,976
+42,960
| +23% | +$1.01M | ﹤0.01% | 2189 |
|
|
2025
Q3 | $4.14M | Buy |
183,016
+16,881
| +10% | +$394K | ﹤0.01% | 2315 |
|
|
2025
Q2 | $2.88M | Sell |
166,135
-475,262
| -74% | -$8.8M | ﹤0.01% | 2430 |
|
|
2025
Q1 | $14M | Buy |
641,397
+37,741
| +6% | +$1.04M | ﹤0.01% | 1603 |
|
|
2024
Q4 | $19.3M | Sell |
603,656
-457
| -0.1% | -$13.7K | ﹤0.01% | 1506 |
|
|
2024
Q3 | $17.4M | Sell |
604,113
-498,720
| -45% | -$18.5M | ﹤0.01% | 1530 |
|
|
2024
Q2 | $42.3M | Buy |
1,102,833
+340,718
| +45% | +$15.4M | 0.01% | 1084 |
|
|
2024
Q1 | $44.8M | Buy |
762,115
+243,278
| +47% | +$15.5M | 0.01% | 1088 |
|
|
2023
Q4 | $31.1M | Sell |
518,837
-21,839
| -4% | -$1.11M | 0.01% | 1210 |
|
|
2023
Q3 | $20.6M | Sell |
540,676
-611,720
| -53% | -$26.9M | 0.01% | 1319 |
|
|
2023
Q2 | $105M | Buy |
1,152,396
+111,415
| +11% | +$9.61M | 0.03% | 706 |
|
|
2023
Q1 | $68.7M | Buy |
1,040,981
+540,194
| +108% | +$31.2M | 0.02% | 834 |
|
|
2022
Q4 | $25.9M | Sell |
500,787
-102,466
| -17% | -$5.43M | 0.01% | 1240 |
|
|
2022
Q3 | $41.2M | Buy |
603,253
+429,625
| +247% | +$25.4M | 0.01% | 972 |
|
|
2022
Q2 | $7.85M | Buy |
173,628
+40,445
| +30% | +$1.84M | ﹤0.01% | 2007 |
|
|
2022
Q1 | $6.77M | Buy |
133,183
+84,634
| +174% | +$3.74M | ﹤0.01% | 2208 |
|
|
2021
Q4 | $2.29M | Sell |
48,549
-6,189
| -11% | -$244K | ﹤0.01% | 2745 |
|
|
2021
Q3 | $1.8M | Sell |
54,738
-542,178
| -91% | -$30.5M | ﹤0.01% | 2855 |
|
|
2021
Q2 | $37.7M | Buy |
596,916
+56,809
| +11% | +$2.93M | 0.01% | 1221 |
|
|
2021
Q1 | $23.2M | Sell |
540,107
-20,985
| -4% | -$993K | 0.01% | 1440 |
|
|
2020
Q4 | $32.1M | Sell |
561,092
-165,685
| -23% | -$7.01M | 0.01% | 1198 |
|
|
2020
Q3 | $21.9M | Buy |
726,777
+154,664
| +27% | +$4.62M | 0.01% | 1254 |
|
|
2020
Q2 | $18.7M | Buy |
572,113
+214,437
| +60% | +$6.89M | 0.01% | 1307 |
|
|
2020
Q1 | $9.58M | Buy |
+357,676
| New | +$12.7M | ﹤0.01% | 1547 |
|
|
2019
Q3 | – | Sell |
-40,779
| Closed | -$1.03M | – | 3672 |
|
|
2019
Q2 | $1.03M | Buy |
+40,779
| New | +$830K | ﹤0.01% | 3056 |
|
Other funds holding APLS
Invesco's APLS Position: Q2 2026 in Review
Invesco sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 437,868 shares — an estimated $17.6M sold.
Invesco first reported a position in APLS in Q2 2019 and held it in 26 quarters. The position peaked at $105M in Q2 2023. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Invesco reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Invesco sold 437,868 Apellis Pharmaceuticals shares in Q2 2026, an estimated $17.6M.
- Invesco first reported a position in Apellis Pharmaceuticals in Q2 2019 and held it in 26 quarters.
- Invesco's Apellis Pharmaceuticals position peaked at $105M in Q2 2023.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.